Type 1 Diabetes TrialNet: Clinical Centers (U01)

1 型糖尿病 TrialNet：临床中心 (U01)

• 批准号: 8468689
• 负责人: PHILIP RASKIN
• 金额: $ 54.78万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8468689
• 关键词: Address; Adverse effects; Affect; Amputation; Anti-Inflammatory Agents; Anti-inflammatory; Beta Cell; Blindness; Cell physiology; Child; Clinical; Clinical Trials; Complications of Diabetes Mellitus; Cost Savings; Development; Diabetes Mellitus; Disease; Drug usage; Goals; Health Care Costs; Human; Immune; Individual; Insulin; Insulin-Dependent Diabetes Mellitus; Intervention; Islets of Langerhans; Kidney Failure; Life Style; Mediating; Pharmaceutical Preparations; Pioglitazone; Prevention; Property; Protocols documentation; Regulatory T-Lymphocyte; Research; Savings; Series; T-Lymphocyte; Testing; Toxic effect; United States; Work; base; design; diabetic patient; experience; immunoregulation; innovation; insulin secretion; patient population; prevent; public health relevance; response; success; therapy design; young adult

DESCRIPTION (provided by applicant): Type 1 diabetes affects more than one million individuals, mostly children and young adults, in the United States and many more worldwide. It occurs in genetically predisposed individuals as a consequence of immune-mediated destruction of the pancreatic islet insulin-secreting beta cells. The present treatment for Type 1 diabetes, when implemented properly, can delay or prevent the long-term complications of diabetes (i.e., blindness, renal failure, and amputation). However, proper diabetes treatment is quite difficult to do, expensive, and very invasive to the diabetic patient's lifestyle. Diabetes is also a major factor in health care costs. Is it possible to prevent Type 1 diabetes or to preserve insulin secretion once diabetes has develped? Several immune interventions have been tried in genetically susceptible individuals without success. Other trials have been attempted to intervene early in the course of Type 1 diabetes, in order to preserve beta cell function. These immune interventions using drugs with potential toxicity have failed. Thus, the identification of agents which either prevent the disease or slow its progression would result in major health care cost savings and reduce complications related to diabetes in addition to the huge individual savings in terms of not having the disease. Our long-term goal is to prevent the development of Type 1 diabetes through the use of innovative based therapies designed to prevent the development of the disease in genetically predisposed individuals. The objectives of this application, in pursuit of that goal and in response to the RFA, is completion of the TrialNet protocols and to continue to develop and test innovative interventions to prevent or slow the progression of Type 1 diabetes. One such innovative approach to slow the progression of Type 1 diabetes is our proposed protocol, "Pioglitazone Preserves Insulin Secretion in Type 1 Diabetes." The proposed work is innovative because it utilitizes a drug that is in wide spread use with low toxicity yet has immunomodulation and anti- inflamatory properties. We have also designed a series of mechanistic studies to examine whether the anti-inflammatory properties of the drug operate by influencing regulatory T-cells.

描述（由申请人提供）：1型糖尿病影响超过一百万人，主要是儿童和年轻人，在美国和世界各地更多。由于免疫介导的胰岛胰岛素分泌β细胞的破坏，它发生在遗传易感个体中。本发明的1型糖尿病治疗方法，当适当实施时，可以延迟或预防糖尿病的长期并发症（即，失明、肾衰竭和截肢）。然而，适当的糖尿病治疗是相当困难的，昂贵的，并且对糖尿病患者的生活方式具有很大的侵入性。糖尿病也是医疗保健费用的一个主要因素。有没有可能预防1型糖尿病或在糖尿病发生后保持胰岛素分泌？在遗传易感个体中尝试了几种免疫干预措施，但没有成功。其他试验已经尝试在1型糖尿病的早期进行干预，以保护β细胞功能。这些使用具有潜在毒性的药物的免疫干预已经失败。因此，鉴定预防疾病或减缓其进展的药剂将导致主要的卫生保健成本节省，并减少与糖尿病相关的并发症，以及在不患有该疾病方面的巨大个人节省。我们的长期目标是通过使用创新的基础疗法来预防1型糖尿病的发展，这些疗法旨在预防遗传易感个体的疾病发展。为了实现这一目标并响应RFA，本申请的目的是完成TrialNet协议，并继续开发和测试创新干预措施，以预防或减缓1型糖尿病的进展。其中一种减缓1型糖尿病进展的创新方法是我们提出的方案，“吡格列酮保护1型糖尿病的胰岛素分泌。“这项拟议的工作是创新的，因为它利用了一种广泛使用的低毒性药物，但具有免疫调节和抗炎特性。我们还设计了一系列机制研究，以检查药物的抗炎特性是否通过影响调节性T细胞来发挥作用。